Shimadzu?s LCMS-8050 triple quadrupole LC-MS/MS meets the growing demand for trace-level quantitation in clinical research and other markets.
LCMS-8050 - Extraordinary sensitivity in the world’s fastest triple quadrupole mass spectrometer
Shimadzu’s LCMS-8050 triple quadrupole LC-MS/MS meets the growing demand for trace-level quantitation in clinical research and other markets. It incorporates proprietary ultrafast technologies as well as a ion source and collision cell technology. As the flagship model of Shimadzu’s UFMS (Ultra-Fast Mass Spectrometry) product line, the LCMS-8050 features high sensitivity, high data quality and the world’s fastest data acquisition rates. Delivering attogram-level (10-18 grams) sensitivity and possessing unsurpassed ruggedness, the LCMS-8050 achieves its improved sensitivity through two important technologies:
• Newly designed Heated ESI source improves desolvation and enhances ionization efficiency with the addition of a heated gas used in combination with the nebulizer gas
• UFsweeper®III collision cell enhances CID efficiency by optimizing the collision cell pressure.
The world’s fastest data acquisition rates
The newly engineered high voltage power supply enables a maximum scan rate of 30,000 u/sec and a 5 msec polarity switching time, making the LCMS-8050 combined with Nexera UHPLC the ideal platform for laboratory productivity. It is now possible to include 1,000 events with up to 32 channels per event for a maximum of 32,000 MRMs per analysis.
Company name: Shimadzu Europa GmbH
Website: www.shimadzu.eu
E-mail: shimadzu@shimadzu.eu
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.